No room for error: preparing for inevitable variability in the cell and gene therapy supply chain

Jamie Margolis is the Director of Product Development Operations for Be The Match BioTherapies, and has more than 9 years of experience managing the complexities of cellular therapies. Jamie and her team work closely with clients to understand their unique needs and determine how Be The Match BioTherapies can best support delivery of services based on client specifications. It is her team’s responsibility to ensure the smooth operational delivery of products and services to clients, such as supply chain management, development and management of collection networks, identifying and sourcing allogeneic donor cells, as well as regulatory compliance.

She joined Be The Match BioTherapies’ parent organization, the National Marrow Donor Program/Be the Match, in 2009 and spent the first 6 years in patient case management supporting the operational needs of health care providers for stem cell transplant and troubleshooting unexpected disruptions that occur throughout the complex product delivery process. Jamie has worked for Be The Match BioTherapies since it was established in 2016. She holds her Ph.D. in Molecular Biology and Genetics from the University of Minnesota.

Jason Krentz is currently Chief Technology Officer at Tmunity Therapeutics, a private clinical-stage T cell immunotherapy company. Jason has extensive technical leadershipexperience in the development and manufacturing of biologic and cell-based products atestablished and emerging pharmaceutical and biotech companies. He joined Tmunity from Endo Pharmaceuticals where he was Vice President of Endo’s biologics manufacturing and technical development organization. Prior to Endo, Jason was Vice President of Technical Operations and Head of CMC Project Management at Auxilium Pharmaceuticals, responsible for global manufacturing and supply chain, technical development and alliance management activities.

Prior to joining Auxilium, Jason was Head of Technical Operations at Tengion, a clinical stage developer of autologous regenerative medicine therapies. Earlier in this career, he worked at Centocor / Johnson & Johnson where he held a variety of technical roles including head of upstream manufacturing operations at a large-scale mammalian cell culture facility. Jason holds an MBA from St. Joseph’s University and a BS in Materials Science and Engineering from the University of Michigan.